Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. Summary
    4578   JP3188220002

OTSUKA HOLDINGS CO., LTD.

(4578)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
4146 4051 4036 4072 4050 Last
4634100 1915600 1106300 1055300 793100 Volume
+2.88% -2.29% -0.37% +0.89% -0.54% Change
Estimated financial data (e)
Sales 2021 1 470 B 12 950 M 12 950 M
Net income 2021 158 B 1 391 M 1 391 M
Net cash position 2021 271 B 2 387 M 2 387 M
P/E ratio 2021 13,8x
Yield 2021 2,49%
Sales 2022 1 519 B 13 378 M 13 378 M
Net income 2022 159 B 1 404 M 1 404 M
Net cash position 2022 351 B 3 088 M 3 088 M
P/E ratio 2022 13,7x
Yield 2022 2,54%
Capitalization 2 197 B 19 361 M 19 349 M
EV / Sales 2021 1,31x
EV / Sales 2022 1,22x
Nbr of Employees 33 151
Free-Float 75,4%
More Financials
Company
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (64.4% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale... 
Sector
Pharmaceuticals
Calendar
12/29
More about the company
Ratings of Otsuka Holdings Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about OTSUKA HOLDINGS CO., LTD.
12/02Unichem Laboratories Gets US FDA Nod for Aripiprazole Tablets
MT
11/19Nikkei rises on chipmakers, energy boost; SoftBank drops
RE
11/11Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December..
PU
11/11Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending December..
CI
11/05GSK says anaemia drug shows positive safety profile
RE
11/01GlaxoSmithKline Rebuffs Reports on Potential Bid for Canada's Aurinia Pharmaceuticals
MT
10/29Akebia Says Partner Otsuka Files Initial MAA for Vadadustat with European Medicines Age..
MT
10/06OTSUKA : ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the T..
BU
10/06LUPIN : Gets US FDA's Approval for Brexpiprazole Tablets
MT
10/04Sumitomo Dainippon Sells License for Psychiatry and Neurology Compounds to Otsuka for $..
MT
09/30Health Care Stocks Closing Slightly Lower After Early Gains
MT
09/30Health Care Stocks Unable to Sustain Early Rise
MT
09/30OPTIMIZERX : Hires Edward Stelmakh as CFO, COO
MT
09/30OTSUKA : Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and Licen..
PU
09/28Mcquade Center for Strategic Research and Development Launches the Otsuka Digital Pione..
CI
More news
News in other languages on OTSUKA HOLDINGS CO., LTD.
11/25Tokyo lâche 3% en séance face aux craintes autour du nouveau variant
11/24Tokyo plombée par la hausse des taux d'intérêt américains
11/11Otsuka Holdings Co., Ltd. révise ses prévisions de bénéfices pour l'exercice financier ..
11/01GlaxoSmithKline réfute les rapports sur une offre potentielle pour la société canadienn..
10/29Le partenaire d'Akebia, Otsuka, dépose une première AMM pour le vadadustat auprès de l'..
More news
Chart OTSUKA HOLDINGS CO., LTD.
Duration : Period :
Otsuka Holdings Co., Ltd. Technical Analysis Chart | 4578 | JP3188220002 | MarketScreener
Technical analysis trends OTSUKA HOLDINGS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 4 050,00 JPY
Average target price 4 658,33 JPY
Spread / Average Target 15,0%
EPS Revisions
Managers and Directors
Tatsuo Higuchi President, CEO & Representative Director
Yuko Makino Chief Financial Officer & Director
Ichiro Otsuka Chairman
Yukitakeshi Matsutani Independent Outside Director
Yasushi Sekiguchi Independent Outside Director